ZOLMITRIPTAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21N3O2
Molecular Weight	287.3568
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCC1=CNC2=C1C=C(C[C@H]3COC(=O)N3)C=C2

InChI

InChIKey=ULSDMUVEXKOYBU-ZDUSSCGKSA-N

InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C16H21N3O2
Molecular Weight	287.3568
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9154322

Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and moderate affinity for 5-HT1A receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Zomig for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction, and inhibition of pro-inflammatory neuropeptide release.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 1d (5-HT1d) receptor 52 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9154322	Agonist 2662
Serotonin 1b (5-HT1b) receptor 45 Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9154322	Agonist 2662

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine with aura 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf	Palliative		Approved 8360	ZOMIG Approved Use INDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Launch Date 8.80416E11
Migraine without aura 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf	Palliative		Approved 8360	ZOMIG Approved Use INDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Launch Date 8.80416E11

C_max

Value	Dose	Analyte	Population
5.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
4.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
5.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
10.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
9.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Analyte	Population
16.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
23.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
30.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
32.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
32.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
54.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
55.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
71.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
75% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020768s023,021231s014,021450s010lbl.pdf	unknown, unknown		ZOLMITRIPTAN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 mg single, intranasal Highest studied dose Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	unhealthy, 41.7 ± 10.4 n = 783 Health Status: unhealthy Condition: Migraine Age Group: 41.7 ± 10.4 Sex: M+F Population Size: 783 Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	Disc. AE: Taste abnormality, Migraine aggravated... AEs leading to discontinuation/dose reduction: Taste abnormality (0.4%) Migraine aggravated (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845
50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13	Other AEs: Sedation... Other AEs: Sedation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13
5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	Disc. AE: Arrhythmia, Cerebral hemorrhage... AEs leading to discontinuation/dose reduction: Arrhythmia Cerebral hemorrhage Subarachnoid hemorrhage Stroke Gastrointestinal ischemia Peripheral vasoconstriction Serotonin syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Migraine aggravated	0.4% Disc. AE	5 mg single, intranasal Highest studied dose Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	unhealthy, 41.7 ± 10.4 n = 783 Health Status: unhealthy Condition: Migraine Age Group: 41.7 ± 10.4 Sex: M+F Population Size: 783 Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845
Taste abnormality	0.4% Disc. AE	5 mg single, intranasal Highest studied dose Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	unhealthy, 41.7 ± 10.4 n = 783 Health Status: unhealthy Condition: Migraine Age Group: 41.7 ± 10.4 Sex: M+F Population Size: 783 Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845
Sedation		50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13
Arrhythmia	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Cerebral hemorrhage	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Gastrointestinal ischemia	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Peripheral vasoconstriction	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Serotonin syndrome	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Stroke	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Subarachnoid hemorrhage	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709	substrate 1010	substrate 1193 inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509	CYP2C19 985 CYP1A2 1032 P-gp 1527 OATP1A2 61

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0	weak
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0	yes		yes (co-administration study) Comment: The increased exposure to zolmitriptan and 183C91 by cimetidine indicated that a reduction in the total daily recommended dose of zolmitriptan may be necessary when treating migraine patients who are taking nonspecific cytochrome P450 inhibitors or specific cytochrome 1A2 inhibitors. (https://pubmed.ncbi.nlm.nih.gov/18370509/) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1032	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	no	N-desmethyl-zolmitriptan 1
CYP2C9 1010	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	no	N-desmethyl-zolmitriptan 1
CYP2D6 1193	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	no	N-desmethyl-zolmitriptan 1
CYP2C19 985	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak
CYP2C19 985	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak	N-desmethyl-zolmitriptan 1
CYP2C9 1010	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak
CYP3A4 1709	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak	N-desmethyl-zolmitriptan 1
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=25 Page: 25.0	yes
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=25 Page: 25.0	yes
OATP1A2 61	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/22509823/ Page: -	yes
P-gp 1527	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/17524230/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:10124	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10124
ChemicalBook	CB3313219	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3313219
MolPort	MolPort-003-666-626	https://www.molport.com/shop/molecule-link/MolPort-003-666-626
Selleck Chemicals	Zolmitriptan(Zomig)	http://www.selleckchem.com/products/Zolmitriptan(Zomig).html
ZINC	ZINC000000015515	http://zinc15.docking.org/substances/ZINC000000015515
eMolecules	2729142	https://www.emolecules.com/cgi-bin/more?vid=2729142

PubMed

Title	Date	PubMed
Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.	1997 Oct	9399012
Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat.	1998 Jan	9489607
Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.	1998 Jun	9660035
[Mechanism of action of zolmitriptan].	1998 Oct	9859690
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.	1999 Jun	10427351
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.	1999 Mar 5	10193663
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?	2000 Oct	11167903
Global trends in migraine care: results from the MAZE survey.	2002	12196035
Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.	2002	11844897
Transcranial Doppler in migraine attacks before and after treatment with oral zolmitriptan or sumatriptan.	2003 Jan	12864759
Cost considerations of acute migraine treatment.	2004 Mar	15012668
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.	2005 Mar	15900510
Myocardial infarction after taking zolmitriptan.	2005 May	16464313
Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors.	2005 May	15836966
Myalgia and cramps associated with zolmitriptan.	2005 Sep-Oct	16239765
Renal infarction during the use of rizatriptan and zolmitriptan: two case reports.	2006	16615676
Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet.	2006 Dec	17109663
Molecular drug targets and structure based drug design: A holistic approach.	2006 Dec 23	17597912
Acute renal failure in a 17-year-old female with ALL receiving escalating intravenous methotrexate without leukovorin.	2007 Aug	16786587
The 1:1 inclusion compounds zolmitriptan-benzene and zolmitriptan-phenol.	2007 Jul	17609581
Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.	2007 Sep	17883521
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.	2008 Aug	18816299
Triptans and troponin: a case report.	2009 Jun 18	19538745
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram.	2010 Feb	20159412
A new stability indicating HPLC method for related substances in zolmitriptan.	2010 Jan	20582203
Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.	2015 Mar-Apr	24100257

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dose of ZOMIG (zolmitriptan) is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of ZOMIG is 5 mg.

Route of Administration: Oral

In Vitro Use Guide

Stimulation of a Ca(2+)-dependent K(+) current by zolmitriptan was investigated in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Outward K(+) currents (I(K)) were examined in non-transfected C6 glioma cells and in cells expressing cloned human 5-HT(1B) receptors using the patch-clamp technique in the whole-cell configuration. In C6 glioma cells expressing recombinant human 5-HT 1B) receptor, zolmitriptan increased I(K) in a concentration-dependent manner (maximum increase 16.3+/-7.8%, n=5, p<0.001) with a pD(2) value (geometric mean with 95% confidence intervals) of 7.03 (7.90-6.10). Zolmitriptan failed to elicit increases in I(K) in non-transfected C6 cells.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:21:43 UTC 2023` Edited by `admin` on `Wed Jul 05 23:21:43 UTC 2023`
Record UNII	2FS66TH3YW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZOLMITRIPTAN

Official Name

English

Zolmitriptan [WHO-DD]

Common Name

English

311-C-90

Code

English

ZOLMITRIPTAN [USAN]

Common Name

English

zolmitriptan [INN]

Common Name

English

ZOLMITRIPTAN [MART.]

Common Name

English

ZOLMITRIPTAN [EP MONOGRAPH]

Common Name

English

ZOLMITRIPTAN [MI]

Common Name

English

ZOLMITRIPTAN [ORANGE BOOK]

Common Name

English

311C90

Code

English

ZOLMITRIPTAN [VANDF]

Common Name

English

2-OXAZOLIDINONE, 4-((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)-, (S)-

Systematic Name

English

ZOLMITRIPTAN [JAN]

Common Name

English

CVT-427

Common Name

English

(S)-4-[[3-[2-(Dimethylamino)ethyl]indol-5-yl]methyl]-2-oxazolidinone

Systematic Name

English

ZOLMITRIPTAN [USP MONOGRAPH]

Common Name

English

ZOLMITRIPTAN [USP-RS]

Common Name

English

NSC-760383

Code

English

ZOMIG

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QN02CC03